6 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 5 with minor changes only.
Primary completion pushed from Oct 2026 to Jan 2028
Also in this update: Trial sites expanded: 95 → 98 locations; Study completion pushed from Dec 2026 to Mar 2028
Xenon Pharmaceuticals Inc.Phase 3 NCT05716100 Registry history of NCT05716100 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Xenon Pharmaceuticals Inc.Phase 3 NCT07076407 Registry history of NCT07076407 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Xenon Pharmaceuticals Inc.Phase 3 NCT07172516 Registry history of NCT07172516 on ClinicalTrials.gov (opens the registry)
Trial status changed: Enrolling by Invitation → Active, Not Recruiting
Xenon Pharmaceuticals Inc.Phase 3 NCT07217860 Registry history of NCT07217860 on ClinicalTrials.gov (opens the registry)
Trial status changed: Enrolling by Invitation → Active, Not Recruiting
Xenon Pharmaceuticals Inc.Phase 3 NCT06922110 Registry history of NCT06922110 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Aug 2026 to Oct 2026; Trial sites reduced: 51 → 45 locations
Xenon Pharmaceuticals Inc.Phase 3 NCT06775379 Registry history of NCT06775379 on ClinicalTrials.gov (opens the registry)
| Phase 2 | 1 | |
| Phase 3 | 8 |
Depression (5) · Epilepsy (4) · Bipolar Disorder (2)